We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Ellen Lee Ellen Lee is a ...

Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.